Breast cancer, the most prevalent cancer affecting women worldwide, poses a significant
cardio-oncological burden. Despite advancements in novel therapeutic strategies …

Breast cancer is one of the most prevalent types of cancers worldwide, especially for
females. Surgery is the preferred treatment for breast cancer, and various postoperative …

Background There is substantial evidence that systemic anticancer therapies and
radiotherapy can increase the long-term risk of cardiovascular disease (CVD). Optimal …

Anthracyclic (ANT) drugs are widely used for patients with malignant tumors and can
markedly prolong the disease‑free survival rate of patients. As its clinical application …

Aims Doxorubicin‐induced cardiotoxicity (DIC) is a significant cause of mortality in cancer
care. This study was conducted to establish the frequency of DIC in Zimbabwean breast …

Introduction Anthracycline-based chemotherapy increases the risk of cancer therapeutics-
related cardiac dysfunction. Recently, evidences from in vitro experiments and animal …

Background Anthracycline‐based chemotherapy (ABC) is one of the standard therapies
against breast cancer. However, few guidelines are currently available to optimize the use of …

Background: Chemotherapy associated with breast cancer often induces cardiotoxicity,
which compromises patients' health and quality of life. Objective: To verify the effect of …

Background Dose-dense sequential chemotherapy with anthracyclines and taxanes
achieved an 18% reduction of recurrence risk in early breast cancer (BC). The optimal …

FinHer regimen is considered a relatively cardiac safe regimen for Her 2 positive breast
cancer in resource‐limited settings. There is limited data on cardiotoxicity of this regimen …